Drug interactions with antiepileptic agents;Arzneimittelwechselwirkungen mit antiepileptika

Wiener Klinische Wochenschrift

Volumn 116, Issue 4, 2004, Pages 112-118

  Turnheim, Klaus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antiepileptics; Cytochrome P450; Drug interactions; Enzyme induction; Inhibition of drug biotransformation

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BARBEXACLONE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CLOZAPINE; CYTOCHROME P450; DIAZEPAM; DICLOFENAC; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; MEPHENYTOIN; OXCARBAZEPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INDUCTION; REVIEW;

EID: 1542380091     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03040747     Document Type: Review

References (37)

1. Janz D, Schmidt D (1974) Anti-epileptic drugs and failure of oral contraceptives. Lancet i: 1113
2. Laengner H, Detering K (1974) Ant-epileptic drugs and failure of oral contraceptives. Lancet ii: 600
3. Hempel E, Klinger W (1976) Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. Drugs 12: 442-448
4. Lewis JR (1979) Oral contraceptive and antiepileptic drug interaction resulting in contraceptive failure. J Am Med Assoc 241: 2743
5. McAuley JW, Anderson GD (2002) Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 41: 559-579
6. Hachad H, Ragueneau-Majlessi I, Levy RH (2002) New aniepileptic drugs: review on drug interactions. Ther Drug Monit 24: 91-103
7. Patsalos PN, Fröscher W, Pisani F, van Rijn CM (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43: 365-385
8. Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontology 38: 843-853
9. Cloyd JC, Lackner TE, Leppik IE (1994) Antiepileptics in the elderly: pharmacoepidemiology and pharmacokinetics. Arch Family Med 7: 589-598
10. Hansten PD (2001) Important drug interactions and their mechanisms. In: Katzung BG (ed) Basic and clinical pharmacology, 8th edn. Lange Medical Books/McGraw-Hill, New York, pp 1122-1133
11. Paneitz A, Messner K, Krömer HK (2000) Arzneimittelinteraktionen: neue Mechanismen und klinische Relevanz. Internist 41: 338-343
12. Seymour KM, Routledge PA (1998) Important drug interactions in the elderly. Drugs Aging 12: 485-494
13. Turnheim K (2002) Arzneimittelinteraktionen in der Geriatrie. In: Böhmer F, Rhomberg HP, Weber E (Hrsg) Grundlagen der Geriatrie. Verlagshaus der Ärzte GmbH, Wien, S 126-134
14. Stockley IH (1999) Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management. Pharmaceutical Press, London
15. Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A (1980) Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 28: 779-789
16. Bourgeois BFD (2000) Pharmacokinetic properties of current antepileptic drugs: what improvements are needed? Neurology 55 [Suppl 3]: S11-S16
17. Wilkinson GR (2001) Pharmacokinetics, the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 3-29
18. Charney DS, Mihic J, Harris RA (2001) Hypnotics and sedatives. In: Hardman JG, Limbird LE (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 399-427
19. Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32: 554-563
20. Smith C (2001) Drug interactions between psychoactive agents and antiepileptic agents. Epilepsy Behavior 2: 92-105
21. Spina E, Scordo MG (2002) Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19: 299-320
22. Bazil CW, Pedley TA (2003) Clinical pharmacology of antiepileptic drugs. Clin Neuropharmacol 26: 38-52
23. May TW, Rambeck B, Jürgens U (2002) Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 24: 366-374
24. Berry DJ, Besag FM, Pool F, Natarajan J, Doose D (2002) Lack of an effect of topiramate on lamotrigine serum concentrations. Epilepsia 43: 818-823
25. Morris RG, Black AB, Lam E, Wesley IS (2000) Clinical study of lamotrigin and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit 22: 656-660
26. Kapetanovic IM, Kupferberg HJ, Poner RJ, Theodore W, Schulman E, Perry JK (1981) Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 29: 480-486
27. Rambeck B (1998) Antiepileptic drug interactions in polytherapy. Epileptologia 2: 43-53
28. Sabers A, Ohman I, Christensen J, Tomson T (2003) Oral contraceptives reduce lamotrigin plasma levels. Neurology 26: 570-571
29. Mula M, Trimble MR (2003) Pharmacokinetic interaction between antiepileptic and antidepressant drugs. World J Biol Psychiatry 4: 21-24
30. Kaufman KR, Gerner R (1998) Lamotrigin toxicity secondary to sertraline. Seizure 7: 163-165
31. Potschka H, Fedrowitz M, Löscher W (2001) P-glycoprotein and multidrug-resistance associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepin in the brain. Neuroreport 12: 3557-3560
32. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Anett GM, Raffel C (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1-6
33. Sisodiya SM, Lin W-R, Harding BN, Squirer MV, Thom M (2002) Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125: 22-31
34. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SMG, Haefeli WE (2003) Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 307: 262-267
35. Shukla S, Godwin CD, Long LEB, Miller MG (1984) Lithium-carbamazepin neurotoxicity and risk factors. Am J Psychiatry 141: 1604-1605
36. Walker MC, Patsalos PN (1995) Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 67: 351-384
37. Ben-Menachem E (2003) Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 4: 2079-2088